Watchlist for February 27, 2006

The QQQQ is gapping up this morning but it's still about 10 cents away from its 50-day moving average. That moving average has marked the high for the day each of the last two sessions. The Qs have not closed above the 50 DMA for all of February, so that level bears watching.

Potential swing trades:

See one of the recent 'Chart Reading' posts for some potential swing candidates.

Potential day trades:

(From Briefing.com)

Gapping Down

Gapping down on disappointing earnings/guidance: LTON -3.4%, WRNC -2.2%, NEM -2.1% (down in sympathy: PD -2.1%)... Other News: AVAN -9.5% (Phase IIB study does not meet endpoint), SYNM -7% (60 Minutes story profiles coal-to-liquids, but does not mention co specifically), RTK -6.7% (same), MCS -4.6%, ASYT -4.5% (Citigroup downgrade), ALGN -4.4% (mentioned in Barron's as a shorting opportunity), SNTS -4% (FDA delays action date for Zegerid by 1 day), VOD -3.7% (lowers forecast), LRCX -3.1% (Citigroup downgrade).

Gapping Up

Gapping up on earnings/guidance: ENMC +10%, NFI +8.4%, TOPT +4.1%, LOW +3.9%... Other News: SVC +26% (to be acquired by AH), PCNTF +19% (MediaRing to make offer for the co; also wins contract), FCEL +10% (selected by Dept of Energy to develop a coal-based system), CYTO +10% (clinical data), NABI +8% (terminates agreement with Cambrex), IMCO +7.6%, ELON +7%, IACI +4.9% (mentioned positively in Barron's), KONG +4.7% (reports tonight), PEIX +4.6%, ARIA +4.2%, SNDK +4% (Citigroup upgrade), FLSH +3.6% (Citigroup upgrade), INFA +3.6% (IBD mention), SONS +3.2% (360networks selects co for VoIP service), TS +3%, BRLC +2.9%, SNDA +2.7% (reports tonight), ADSK +2.7% (Deutsche upgrade), GRMN +2.5% (mentioned positively in Barron's), TXU +2.5% (GE and Macquarie vie to buy stake in TXU's energy-delivery assets - WSJ), GM +2.5% (DIrecTV to buy back 100 mln shares from GM's pension funds), GERN +2.2% (profiled on 60 Minutes), Bird flu stocks are strong ahead of bird flu summit: GNBT +9%, BCRX +5.6%, HEB +4%, NVAX +2.2%... Under $3: DCN +38% (continues discussions with banks), HIV +16%, PPHM +11% (clinical data), TMTA +5%.